Posts by: Carolina Henriques

Carolina Henriques

Carolina holds a BSc in Anthropology and a MSc in Urban Studies., and brings her interdisciplinary skills to her writing on a range of different topics in science, research and advocacy news.

June 13, 2016June 13, 2016

#EULAR 2016: UK Rheumatologists Often Prescribe Outside NICE Guidlines

News

A study presented at the European League Against Rheumatism Annual Congress (EULAR 2016) revealed that several factors not related to cost might influence the prescription of TNF inhibitors for patients with rheumatoid arthritis (RA). ... Read more

June 6, 2016June 6, 2016

#EULAR2016 – AbbVie to Show New Data on RA Therapy Humira, Present Research on Drug Candidate ABT-494

News

AbbVie has announced that key data regarding Humira (adalimumab) will be presented at the Annual European Congress of Rheumatology (EULAR 2016) June 8-11 in London, England. The data includes investigational research along with ... Read more

April 29, 2016April 29, 2016

Research into Biologic Effects of Combo Treatments for Rheumatoid Arthritis Is Topic of 2 Webinars

News

Dr. Ernest Choy, FRCP, head of Rheumatology at Cardiff University’s Institute of Infection and Immunity, will lead two webinars examining how the biologic effects of combination treatments can be investigated using an in ... Read more

April 8, 2016April 8, 2016

FDA Approves Inflectra for Patients with Rheumatoid Arthritis, Other Conditions

News

Celltrion announced that Inflectra (biosimilar infliximab) has been approved by the U.S. Food and Drug Administration (FDA) for all the same indications that Remicade (infliximab) is approved, including rheumatoid arthritis ... Read more

February 24, 2016May 23, 2016

Potential RA Treatment, a Biosimilar to Infliximab, Acquired by Sandoz for Development in Europe

News

Sandoz, a Novartis company focused on generic pharmaceuticals, announced it has acquired the rights to Pfizer’s biosimilar to infliximab (PF-06438179) in the European Economic Area (EEA) as a possible treatment for autoimmune diseases ... Read more

February 15, 2016May 23, 2016

AbbVie Invites Rheumatoid Arthritis Students to Apply for $15,000 Scholarships

News

AbbVie has started a new scholarship program to help outstanding students with rheumatologic diseases, such as rheumatoid arthritis (RA), pursue higher education. A total of 15 scholarships, each worth $15,000, are available for ... Read more

February 12, 2016February 12, 2016

More than $3.7 Million in RA Research Funded by Arthritis Foundation Scientific Discovery Awards

News

The Arthritis Foundation announced the 11 foundation’s 2015 Scientific Discovery Awards for their innovative research in arthritis and related diseases. This was the foundation’s first request for proposals (RFP), with revised eligibility criteria so that ... Read more

February 1, 2016February 1, 2016

Treating Severe Rheumatoid Arthritis Gets Boost With Health Agency’s Recommendation

News

Britain’s National Institute for Health and Care Excellence (NICE) has issued a final guidance recommending the use of seven specific biological disease modifying drugs (DMARDs) as options for treating severe rheumatoid arthritis ... Read more

January 29, 2016May 23, 2016

AbbVie Launches Phase 3 Trial for Rheumatoid Arthritis

News

AbbVie announced the start of a robust Phase 3 clinical trial to analyze the use of ABT-494 – an investigational oral selective JAK1 inhibitor – in the treatment of rheumatoid arthritis (RA). The ... Read more

January 25, 2016May 23, 2016

Rheumatoid Arthritis Drug Candidate Advances to FDA’s New Drug Application Program

News

Indianapolis-based Eli Lilly & Company and Incyte Corp announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of baricitinib, a ... Read more